Vismodegib Safe, Effective in Twelve-Month Study Update

Share this content:

the Cancer Therapy Advisor take:

Vismodegib is safe and effective in the management of advanced basal cell carcinoma (BCC), according to a study published in the Journal of the American Academy of Dermatology.

In a multinational, multicenter, nonrandomized, two-cohort study, researchers led by Aleksander Sekulic, MD, of the Mayo Clinic looked at patients with measurable and histologically confirmed locally advanced or metastatic BCC who took oral vismodegib.

Primary outcome was objective response rate, both complete and partial, which was assessed by an independent review facility.

The researchers found that after 12 months of primary analysis, median duration of exposure to vismodegib was 12.9 months. In patients with metastatic disease, objective response rate increased from 30.3 percent to 33.3 percent, while in those with locally advanced disease, it increased from 42.9 percent to 47.6 percent.

In addition, median duration of response in patients with locally advanced disease increased from 7.6 to 9.5 months.

“The 12-month update of the study confirms the efficacy and safety of vismodegib in management of advanced BCC,” the authors concluded.

NSCLC patients with African-American ancestry may not differ from European backgrounds in somatic dr
Vismodegib is safe and effective in the management of advanced basal cell carcinoma.
Primary analysis from the pivotal ERIVANCE BCC study resulted in approval of vismodegib, a Hedgehog pathway inhibitor indicated for treatment of adults with metastatic or locally advanced basal cell carcinoma (BCC) that has recurred after surgery or for patients who are not candidates for surgery or radiation.
READ FULL ARTICLE From www.jaad.org

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters